Comment | Published:

Impact of the Innovative Medicines Initiative on vaccine development

Nature Reviews Drug Discovery volume 17, pages 769770 (2018) | Download Citation

Since its launch a decade ago, the European Innovative Medicines Initiative (IMI), a leading public–private partnership in life sciences, has catalysed scientific breakthroughs and the development of strategies to address complex challenges in various biomedical fields. Here, we discuss the progress of IMI projects related to vaccine research and development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans. PLoS ONE 11, e0157066 (2016).

  2. 2.

    et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci. Transl Med. 9, eaaj1701 (2017).

  3. 3.

    et al. Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open 7, e018594 (2017).

  4. 4.

    et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine 35, 238–247 (2017).

  5. 5.

    et al. The ADVANCE Code of Conduct for collaborative vaccine studies. Vaccine 35, 1844–1855 (2017).

Download references

Acknowledgements

The authors are grateful to L. Cochard (SCINNOV) for helpful discussions, and E. Oe and U. Krause (both GSK) for scientific writing services and publication management, respectively.

Author information

Affiliations

  1. GSK, Rixensart, Belgium.

    • Philippe Denoel
  2. Sanofi Pasteur, Marcy-l'Étoile, France.

    • Patricia Londoño-Hayes
  3. European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium.

    • Magda Chlebus
  4. Vaccines Europe/EFPIA, Brussels, Belgium.

    • Magdalena Rodriguez de Azero

Authors

  1. Search for Philippe Denoel in:

  2. Search for Patricia Londoño-Hayes in:

  3. Search for Magda Chlebus in:

  4. Search for Magdalena Rodriguez de Azero in:

Competing interests

The authors declare the following conflicts: P.D. is an employee of the GSK group of companies. P.L.H. is an employee of Sanofi Pasteur. M.C. and M.R.A. are employees of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Functions of the authors in IMI: P.D. is the chair of the Vaccines Europe R&D Working Group, a member of the Infections Control Strategic Governing Group and a member of the BioVacSafe and PERISCOPE projects. P.L.H. is a member of the Vaccines Europe R&D Working Group, a member of the Immunology Strategic Governing Group for Vaccines Europe, leader of the FLUCOP project, EFPIA co-leader of the PERISCOPE project and oversees the IMI Portfolio on Vaccines at Sanofi Pasteur. M.C. is coordinating EFPIA input into IMI strategy development and idea/project generation and is a deputy member of the IMI Governing Board. M.R.A. is coordinating the Vaccines Europe members input to vaccine projects generation.

Corresponding author

Correspondence to Philippe Denoel.

Supplementary information

PDF files

  1. 1.

    Supplementary Figure

    Timeline of IMI vaccine consortia

  2. 2.

    Supplementary Table

    Objectives and key achievements of representative IMI vaccine projects

  3. 3.

    Supplementary Box

    Overview of IMI vaccine project budgets

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.72

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing